CircINTS4 Facilitates Chemoresistance of TNBC by Competitively Binding MiR-129-5p/POM121 Axis

Overview

Journal J Oncol

Specialty Oncology

Date 2022 Apr 14

PMID 35419056

Authors

Qian Tang

Feidu Zhou

Chuanguang Yang

Jue Dai

Jintao Li

Yanxian He

Affiliations

Soon will be listed here.

Abstract

Objectives: To detect the expression of circular RNA (circRNA) circINTS4 in triple-negative breast cancer (TNBC) and to analyze the relationship between the expression of circRNA circINTS4 and the clinicopathological characteristics and chemotherapy resistance of patients with TNBC.

Methods: Bioinformatics was used to predict that circINTS4 and POM121 could bind to miR-129-5p, and dual luciferase reporter genes proved that circINTS4 could bind to miR-129-5p and miR-129-5p could bind to POM121. RNA immunoprecipitation (RIP) and RNA pull-down experiments confirmed that circINTS4 binds to miR-129-5p. The correlation among circINTS4, miR-129-5p, and POM121 was detected by qRT-PCR.

Results: In ADR-resistant TNB cells, circINTS4 was significantly up-regulated, miR-129-5p was down-regulated, and POM121 protein expression was significantly up-regulated. Experimental results showed that circINTS4 knockdown inhibited proliferation, migration, invasion, and autophagy. Knocking down miR-129-5p or overexpression of POM121 reversed the inhibitory effect of sh-circints4 on the development of ADR-resistant TNBC cells. In addition, CIRCINTS4 regulates POM121 expression by sponge-adsorbed miR-129-5p. CIRCINTS4 knockdown prevents ADR-resistant tumor growth by regulating the miR-129-5p/POM121 axis in vivo.

Conclusions: CircRNA circINTS4 may act as the ceRNA of miR-129-5p to regulate the expression of target gene POM121, thereby promoting the progress of TNBC molecular mechanism and providing scientific basis for circINTS4 as a new molecular target for clinical diagnosis and drug resistance therapy of TNBC.

Citing Articles

Distinct mRNA expression profiles and miRNA regulators of the PI3K/AKT/mTOR pathway in breast cancer: insights into tumor progression and therapeutic targets.

Sirek T, Krol-Jatrega K, Borawski P, Zmarzly N, Boron D, Ossowski P Front Oncol. 2025; 14():1515387.

PMID: 39850811 PMC: 11754234. DOI: 10.3389/fonc.2024.1515387.

Autophagy Modulation in Therapeutic Strategy of Breast Cancer Drug Resistance.

Wang M, Liu M, Yang C, Hu Y, Liao X, Liu Q J Cancer. 2024; 15(16):5462-5476.

PMID: 39247603 PMC: 11375553. DOI: 10.7150/jca.97775.

Advances in the understanding of nuclear pore complexes in human diseases.

Li Y, Zhu J, Zhai F, Kong L, Li H, Jin X J Cancer Res Clin Oncol. 2024; 150(7):374.

PMID: 39080077 PMC: 11289042. DOI: 10.1007/s00432-024-05881-5.

CircAGFG1 Promotes Ovarian Cancer Progression Through the miR-409-3 p/ZEB1 Axis.

Luo J, Zhong H, Guo M, Xiao P, Cao R, Zhao M Technol Cancer Res Treat. 2024; 23:15330338241252423.

PMID: 38752261 PMC: 11102704. DOI: 10.1177/15330338241252423.

Deciphering the impact of circRNA-mediated autophagy on tumor therapeutic resistance: a novel perspective.

Wang T, He M, Zhang X, Guo Z, Wang P, Long F Cell Mol Biol Lett. 2024; 29(1):60.

PMID: 38671354 PMC: 11046940. DOI: 10.1186/s11658-024-00571-z.

References

Li W, Lee J, Yu S, Wang F, Lv W, Zhang X . Characterization and analysis of the transcriptome response to drought in Larix kaempferi using PacBio full-length cDNA sequencing integrated with de novo RNA-seq reads. Planta. 2021; 253(2):28. DOI: 10.1007/s00425-020-03555-3. View

Moreno-Vega A, Vega-Riveroll L, Ayala T, Peralta G, Torres-Martel J, Rojas J . Adjuvant Effect of Molecular Iodine in Conventional Chemotherapy for Breast Cancer. Randomized Pilot Study. Nutrients. 2019; 11(7). PMC: 6682905. DOI: 10.3390/nu11071623. View

Zhang S, Zheng C, Li D, Bei C, Zhang H, Tian R . Clinical Significance of Expression in Lung Cancer. Genet Test Mol Biomarkers. 2020; 24(12):819-824. DOI: 10.1089/gtmb.2020.0053. View

Wu L, Zhu X, Song Z, Guo M, Liang J, Yan D . FGD5-AS1 facilitates glioblastoma progression by activation of Wnt/β-catenin signaling via regulating miR-129-5p/HNRNPK axis. Life Sci. 2020; 256:117998. DOI: 10.1016/j.lfs.2020.117998. View

Wen Y, Li B, He M, Teng S, Sun Y, Wang G . circHIPK3 promotes proliferation and migration and invasion via regulation of miR‑637/HDAC4 signaling in osteosarcoma cells. Oncol Rep. 2021; 45(1):169-179. PMC: 7709833. DOI: 10.3892/or.2020.7833. View

Prakash O, Hossain F, Danos D, Lassak A, Scribner R, Miele L . Racial Disparities in Triple Negative Breast Cancer: A Review of the Role of Biologic and Non-biologic Factors. Front Public Health. 2021; 8:576964. PMC: 7783321. DOI: 10.3389/fpubh.2020.576964. View

He D, Yang X, Kuang W, Huang G, Liu X, Zhang Y . The Novel Circular RNA Circ-PGAP3 Promotes the Proliferation and Invasion of Triple Negative Breast Cancer by Regulating the miR-330-3p/Myc Axis. Onco Targets Ther. 2020; 13:10149-10159. PMC: 7553664. DOI: 10.2147/OTT.S274574. View

Reitz L, Baptista S, Santos E, Hinnig P, Rockenbach G, Vieira F . Diet Quality Is Associated with Serum Antioxidant Capacity in Women with Breast Cancer: A Cross Sectional Study. Nutrients. 2021; 13(1). PMC: 7824615. DOI: 10.3390/nu13010115. View

Sun H, Sun Y, Yu X, Gao X, Wang H, Zhang L . Analysis of Age-Related Circular RNA Expression Profiles in Mesenchymal Stem Cells of Rat Bone Marrow. Front Genet. 2021; 12:600632. PMC: 8273880. DOI: 10.3389/fgene.2021.600632. View

10.

Shen F, Liu P, Xu Z, Li N, Yi Z, Tie X . CircRNA_001569 promotes cell proliferation through absorbing miR-145 in gastric cancer. J Biochem. 2018; 165(1):27-36. DOI: 10.1093/jb/mvy079. View

11.

El-Sahli S, Hua K, Sulaiman A, Chambers J, Li L, Farah E . A triple-drug nanotherapy to target breast cancer cells, cancer stem cells, and tumor vasculature. Cell Death Dis. 2021; 12(1):8. PMC: 7791049. DOI: 10.1038/s41419-020-03308-w. View

12.

Liu J, Li M, Kong L, Cao M, Zhang M, Wang Y . CircARID1A regulates mouse skeletal muscle regeneration by functioning as a sponge of miR-6368. FASEB J. 2021; 35(2):e21324. DOI: 10.1096/fj.202001992R. View

13.

Lin H, Han H, Wang Y, He D, Sun W, Feng L . Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo. Chin Med. 2020; 15:23. PMC: 7063777. DOI: 10.1186/s13020-020-00305-1. View

14.

Karacin C, Ergun Y, Oksuzoglu O . Saying goodbye to primary endocrine resistance for advanced breast cancer?. Med Oncol. 2021; 38(1):5. DOI: 10.1007/s12032-020-01449-8. View

15.

Anand K, Patel T, Niravath P, Rodriguez A, Darcourt J, Belcheva A . Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy. Sci Rep. 2021; 11(1):82. PMC: 7794349. DOI: 10.1038/s41598-020-80081-y. View

16.

Coyne A, Zaepfel B, Hayes L, Fitchman B, Salzberg Y, Luo E . GC Repeat RNA Initiates a POM121-Mediated Reduction in Specific Nucleoporins in C9orf72 ALS/FTD. Neuron. 2020; 107(6):1124-1140.e11. PMC: 8077944. DOI: 10.1016/j.neuron.2020.06.027. View

17.

Dou D, Ren X, Han M, Xu X, Ge X, Gu Y . CircUBE2D2 (hsa_circ_0005728) promotes cell proliferation, metastasis and chemoresistance in triple-negative breast cancer by regulating miR-512-3p/CDCA3 axis. Cancer Cell Int. 2020; 20:454. PMC: 7491078. DOI: 10.1186/s12935-020-01547-7. View

18.

Thomas M, Davis T, Nell T, Sishi B, Engelbrecht A . Amino Acid Starvation Sensitizes Resistant Breast Cancer to Doxorubicin-Induced Cell Death. Front Cell Dev Biol. 2020; 8:565915. PMC: 7593593. DOI: 10.3389/fcell.2020.565915. View

19.

Li J, Ma M, Yang X, Zhang M, Luo J, Zhou H . Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab. Mol Cancer. 2020; 19(1):142. PMC: 7488427. DOI: 10.1186/s12943-020-01259-6. View

20.

Ortega M, Fraile-Martinez O, Garcia-Montero C, Pekarek L, Guijarro L, Castellanos A . Physical Activity as an Imperative Support in Breast Cancer Management. Cancers (Basel). 2020; 13(1). PMC: 7796347. DOI: 10.3390/cancers13010055. View